These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31200237)

  • 1. Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer.
    Shi C; Wang Q; Liao X; Ge H; Huo G; Zhang L; Chen N; Zhai X; Hong Y; Wang L; Han Y; Xiao W; Wang Z; Shi W; Mao Y; Yu J; Xia G; Liu Y
    Eur J Med Chem; 2019 Sep; 178():352-364. PubMed ID: 31200237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a novel series of imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors.
    Shi C; Wang Q; Liao X; Ge H; Huo G; Zhang L; Chen N; Zhai X; Hong Y; Wang L; Wang Z; Shi W; Mao Y; Yu J; Ke Y; Xia G
    Eur J Med Chem; 2020 May; 193():112239. PubMed ID: 32200202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents.
    Tadesse S; Bantie L; Tomusange K; Yu M; Islam S; Bykovska N; Noll B; Zhu G; Li P; Lam F; Kumarasiri M; Milne R; Wang S
    Br J Pharmacol; 2018 Jun; 175(12):2399-2413. PubMed ID: 28800675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and SAR of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as potent and selective CDK4/6 inhibitors.
    Zhao H; Hu X; Cao K; Zhang Y; Zhao K; Tang C; Feng B
    Eur J Med Chem; 2018 Sep; 157():935-945. PubMed ID: 30165341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and identification of a novel skeleton of N-(pyridin-3-yl) proline as a selective CDK4/6 inhibitor with anti-breast cancer activities.
    Liang JW; Li WQ; Nian QY; Xie SH; Yang L; Meng FH
    Bioorg Chem; 2022 Feb; 119():105547. PubMed ID: 34906858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.
    Wang Y; Liu WJ; Yin L; Li H; Chen ZH; Zhu DX; Song XQ; Cheng ZZ; Song P; Wang Z; Li ZG
    Bioorg Med Chem Lett; 2018 Mar; 28(5):974-978. PubMed ID: 29429832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.
    Bronner SM; Merrick KA; Murray J; Salphati L; Moffat JG; Pang J; Sneeringer CJ; Dompe N; Cyr P; Purkey H; Boenig GL; Li J; Kolesnikov A; Larouche-Gauthier R; Lai KW; Shen X; Aubert-Nicol S; Chen YC; Cheong J; Crawford JJ; Hafner M; Haghshenas P; Jakalian A; Leclerc JP; Lim NK; O'Brien T; Plise EG; Shalan H; Sturino C; Wai J; Xiao Y; Yin J; Zhao L; Gould S; Olivero A; Heffron TP
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2294-2301. PubMed ID: 31307887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma.
    Yuan K; Kuang W; Chen W; Ji M; Min W; Zhu Y; Hou Y; Wang X; Li J; Wang L; Yang P
    Eur J Med Chem; 2022 Jan; 228():114024. PubMed ID: 34875521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel and selective CDK4/6 inhibitors by pharmacophore and structure-based virtual screening.
    Yuan K; Min W; Wang X; Li J; Kuang W; Zhang F; Xie S; Yang P
    Future Med Chem; 2020 Jun; 12(12):1121-1136. PubMed ID: 32400188
    [No Abstract]   [Full Text] [Related]  

  • 10. Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer.
    Freeman-Cook KD; Hoffman RL; Behenna DC; Boras B; Carelli J; Diehl W; Ferre RA; He YA; Hui A; Huang B; Huser N; Jones R; Kephart SE; Lapek J; McTigue M; Miller N; Murray BW; Nagata A; Nguyen L; Niessen S; Ninkovic S; O'Doherty I; Ornelas MA; Solowiej J; Sutton SC; Tran K; Tseng E; Visswanathan R; Xu M; Zehnder L; Zhang Q; Zhang C; Dann S
    J Med Chem; 2021 Jul; 64(13):9056-9077. PubMed ID: 34110834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective CDK4/6 inhibition of novel 1,2,3-triazole tethered acridinedione derivatives induces G1/S cell cycle transition arrest via Rb phosphorylation blockade in breast cancer models.
    Praveenkumar E; Gurrapu N; Kolluri PK; Shivaraj ; Subhashini NJP; Dokala A
    Bioorg Chem; 2021 Nov; 116():105377. PubMed ID: 34670329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a class of diheteroaromatic amines as orally bioavailable CDK1/4/6 inhibitors.
    Fu Y; Tang S; Su Y; Lan X; Ye Y; Zha C; Li L; Cao J; Chen Y; Jiang L; Huang Y; Ding J; Geng M; Huang M; Wan H
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5332-5336. PubMed ID: 29074254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of pteridin-7(8H)-one analogues as highly potent cyclin-dependent kinase 4/6 inhibitors: Synthesis, structure-activity relationship, and biological activity.
    Li Q; Chen L; Ma YF; Jian XE; Ji JH; You WW; Zhao PL
    Bioorg Chem; 2021 Nov; 116():105324. PubMed ID: 34509794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.
    Wang Q; Liu F; Qi S; Qi Z; Yan XE; Wang B; Wang A; Wang W; Chen C; Liu X; Jiang Z; Hu Z; Wang L; Wang W; Ren T; Zhang S; Yun CH; Liu Q; Liu J
    Eur J Med Chem; 2018 Apr; 150():366-384. PubMed ID: 29544149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis.
    Huang Z; Zhao B; Qin Z; Li Y; Wang T; Zhou W; Zheng J; Yang S; Shi Y; Fan Y; Xiang R
    Eur J Med Chem; 2019 Nov; 181():111541. PubMed ID: 31382120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
    Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
    Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of tetrahydronaphthyridine derivatives as bioavailable CDK4/6 inhibitors for cancer therapy.
    Zha C; Deng W; Fu Y; Tang S; Lan X; Ye Y; Su Y; Jiang L; Chen Y; Huang Y; Ding J; Geng M; Huang M; Wan H
    Eur J Med Chem; 2018 Mar; 148():140-153. PubMed ID: 29459274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel series of N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amines as highly potent CDK4/6 inhibitors.
    Tadesse S; Zhu G; Mekonnen LB; Lenjisa JL; Yu M; Brown MP; Wang S
    Future Med Chem; 2017 Sep; 9(13):1495-1506. PubMed ID: 28795589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer evaluation and molecular modeling of multi-targeted kinase inhibitors based pyrido[2,3-d]pyrimidine scaffold.
    Elzahabi HSA; Nossier ES; Khalifa NM; Alasfoury RA; El-Manawaty MA
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):546-557. PubMed ID: 29482389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells.
    Shi X; Quan Y; Wang Y; Wang Y; Li Y
    Bioorg Med Chem Lett; 2021 Feb; 33():127725. PubMed ID: 33316409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.